News
Arexvy is currently approved for use in all individuals aged 60 and older, as well as for high-risk individuals aged 50-59.
The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.
The label expansion sought by GSK is a bid to compete with Pfizer and Moderna in the younger age groups of the RSV vaccine market. Pfizer’s Abrysvo and Moderna’s mRESVIA are both approved to prevent ...
Pharmalittle: We’re reading about Regeneron’s patent maneuvers, FDA rejection letters, and lots more
A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results